Metacarpal Bone Mineral Density by Radiographic Absorptiometry Predicts Fracture Risk in Patients Undergoing Maintenance Hemodialysis
Overview
Authors
Affiliations
The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guideline update suggests bone mineral density testing to assess fracture risk in patients with chronic kidney disease, but dual-energy X-ray absorptiometry is not available in most dialysis facilities. Radiographic absorptiometry is an inexpensive and quick method for evaluating bone mineral density. Therefore, we analyzed a historical cohort of 456 maintenance hemodialysis patients to determine whether metacarpal bone mineral density measured by digital image processing, a computer-assisted radiographic absorptiometry technique, predicts fracture risk. At baseline, the median metacarpal bone mineral density T-score was -2.05 (interquartile range, -3.35 to -0.99). During a mean follow-up of 5.3 years, there were 16 clinical fractures and 11 asymptomatic vertebral fractures as estimated by height loss. Metacarpal bone mineral density T-score was significantly lower in patients who sustained a clinical fracture than in those remaining event-free. Decreasing metacarpal bone mineral density T-score was significantly associated with increased risk of clinical fracture (hazard ratio, 1.41 per 1 standard deviation decrease in bone mineral density T-score [95% confidence interval, 1.09 to 1.83]; the hazard ratio for lowest versus highest tertile was 4.86 [1.03 to 22.92]. Similar associations were observed between metacarpal bone mineral density T-score and vertebral fracture or any fracture. The results were robust to different analysis strategies and were consistent across different subgroups. Thus, radiographic absorptiometry could be a useful tool for primary screening of hemodialysis patients at high risk for fracture. Additional studies are required to determine the predictive ability of radiographic absorptiometry techniques compared to dual-energy X-ray absorptiometry or other established methods.
Komaba H, Imaizumi T, Hamano T, Fujii N, Abe M, Hanafusa N Kidney Int Rep. 2024; 9(10):2956-2969.
PMID: 39430172 PMC: 11489479. DOI: 10.1016/j.ekir.2024.07.008.
Soeda K, Komaba H, Nakagawa Y, Kawabata C, Wada T, Takahashi H J Nephrol. 2024; 37(5):1339-1349.
PMID: 38512372 DOI: 10.1007/s40620-024-01904-z.
Haruyama N, Nakayama M, Yamada S, Tanaka S, Hiyamuta H, Taniguchi M J Bone Miner Metab. 2024; 42(2):253-263.
PMID: 38509305 DOI: 10.1007/s00774-024-01501-x.
Pimentel A, Bover J, Elder G, Cohen-Solal M, Urena-Torres P Diagnostics (Basel). 2021; 11(5).
PMID: 33925796 PMC: 8146279. DOI: 10.3390/diagnostics11050772.
Old and New Drugs for the Management of Bone Disorders in CKD.
Komaba H, Ketteler M, Cunningham J, Fukagawa M Calcif Tissue Int. 2021; 108(4):486-495.
PMID: 33386480 DOI: 10.1007/s00223-020-00788-y.